# Increasing Physician Confidence and Consistency in Controlled Substance Prescribing via Education and Office Policy

Hassan Baiz, MD Bradford Woelke, MD David Kazanowski, MD Elizabeth K. Towner, PhD Eleanor King, MD




### **Outline**



- Importance of safely prescribing controlled substances
- How we addressed the issue
- What we learned
- Where to go from here?

# What is a Controlled Substance?







#### Federal Scheduling: I-V

MI: 2033 or 21/100,000 Overdose Deaths

9% New HIV cases/year from IV drug use



https://www.drugabuse.gov/opioid-summaries-by-state/michigan-opioid-summary



- Federal: Centers for Disease Control calls for regular Urine Drug Screens (UDS)
- State: Michigan law requires
  - "Bona Fide" provider relationship
  - Opioid Let's Start Talking (OST)
- Previous clinic regulation/policy:
  - Written policy and recommendation adherence
  - Requires yearly controlled substance agreement (CSA) and OST and review of MAPS
  - Lack of clear recommendations on UDS and chart documentation
  - Lack of teaching sessions to review and clarify policy and provide education on CSs and UDSs

# Let's Start Talking

\*\* Required for all Schedule II Opiate

Prescriptions \*\*

#### OPIOID START TALKING (MUST BE INCLUDED IN THE PATIENT'S MEDICAL RECORD)

Michigan Department of Health and Human Services

Patient Name		Date of Birth	
Name of Controlled Substa	ance containing an Opioid	1	
Dosage Quar	ntity Prescribed (For a minor, if signature is not the parent	or guardian, the prescriber must limit the	he opioid to a single, 72 hour supply)
Number of refills			
	nce is a drug or other substance that the a potential for abuse. My provider shared		nent Administration has
a. The risks of subs	The risks of substance use disorder and overdose associated with the controlled substance containing an opioid.		
	nental illness and substance use disorders m uired only for minors.)	nay have an increased risk of a	ddiction to a controlled
	th benzodiazepines, alcohol, muscle relaxer e serious health risks, including death or disa		
	o is pregnant or is of reproductive age, the he limited to neonatal abstinence syndrome.	eightened risk of short and long	g-term effects of opioids,
	ation necessary for patients to use the drug s on of the labeling for the controlled substance		in the patient counseling
unwanted control enforcement age	opioids has shown to reduce injury and deat lled substances may be done through comm ncies. Information on where to return your pr gan.gov/deqdrugdisposal.	unity také-back programs, loca	I pharmacies, or local law
	It is a felony to illegally deliver, distribute or share a controlled substance without a prescription properly issued by a licensed health care prescriber.		
	otential benefits and risks of an opioid mo perly managing my medication as stated		y provider along with the
Signature of Prescriber (when prescribing to a minor)			Date
Signature of Patient, if a minor, patient's parent/guardian			Date
Signature of Patient's Representative or other authorized adult			Date
Printed Name of Parent/Gu	nardian; Patient's Representative or other authorized ad	ult	
The Michigan Department	of Health and Human Services (MDHHS) does not A	UTHORITY: PCA 246 of 2017, MCL	333 7303h and MCL 333 7303c

COMPLETION: Required.


permanent revocation.

Probation, limitation, denial, fine, suspension, revocation or

discriminate against any individual or group because of race, religion, age, national origin, color, height, weight, marital status, genetic information, sex, sexual orientation, gender identity or expression, political beliefs or disability.

# **Project Goal**

- Ensure patient safety: residents understand state and clinic CS policies
- 2. Improve resident-reported prescribing confidence by 90% through didactic education on controlled substances policies
- **3. Improve prescribing consistency** of the following documentation by 90%:
  - a. Signed CS agreement
  - b. Signed OST form
  - c. Obtaining UDS



### Plan


- Baseline assessment: chart review to determine physician prescribing consistency during July-September 2019
- Revise CS office policy to clarify UDS and chart documentation recommendations
- Education Intervention: didactics & handouts
- Evaluation
  - Prescribing Confidence: resident selfreport using Likert-scale items and case scenarios
  - Prescribing consistency: post-Intervention chart review (1-month)

# Annual Rx Requirements

Controlled Substance Agreement
Urine Drug Screen
Opioid "Let's Start Talking"


### Do

- CS office policy revised and reviewed with staff and physicians during a weekly didactic session
- Our team presented educational PowerPoint and interactive scenarios to staff and physicians during another weekly didactic session
- Pre-surveys were sent via email approximately one week prior to education followed by post intervention survey immediately following the didactic



# Study


Improved physician controlled substance understanding and prescribing comfort



**GOAL 90%** 

# Study

Improved controlled substance prescribing consistency



**GOAL 90%** 

### Act

- Clarifying CS policies and providing education to physicians led to increases in CS prescribing comfort and prescribing consistency, but we did not reach our goal of 90%.
- While 64% and 59% understood state and office policies respectively, only 41% of physicians felt comfortable prescribing CS. A critical next step is thus to understand what physicians need to increase their comfort with CS prescribing and to use this information to inform subsequent interventions.
- Regarding prescribing consistency, only 40 % of charts had OST compared to 74 % CSA and 76% UDS. Hence, our next step will be to train MAs to assist with policy compliance.
- Finally, We will need to monitor the efficacy of our project over a longer intervention period.

# **Public Health Implications**

- It is a challenge for physicians to know how to legally and safely prescribe CSs given the multiple levels of institutionalized recommendations
- Clear CS policies and taking time to educate physicians on these policies may improve physician confidence in CS prescribing and compliance with CS policies, which may ultimately lead to decreases in overdose deaths.




Figure 2. Michigan rate of overdose deaths involving prescription opioids and the opioid prescribing rate.

https://www.drugabuse.gov/opioid-summaries-by-state/michigan-opioid-summary

# **Questions?**

### References

- (1) Centers for Disease Control and Prevention. (2018). Quality improvement and care coordination: Implementing the CDC guideline for prescribing opioids for chronic pain. *National Center for Injury Prevention and Control, Division of Unintentional Injury Prevention, Atlanta, GA.* Retrieved from https://www.cdc.gov/drugoverdose/pdf/prescribing/CDC-DUIP-QualityImprovementAndCareCoordination-508.pdf
- (1) Center for Disease Control and Prevention. (2011, November 4). Vital signs: Overdoses of prescription pain relievers United States, 1999–2008. *MMWR Morb Mortal Wkly Rep.* 1487–1492.
- (2) Department of Licensing and Regulatory Affairs (LARA) and the Michigan Department of Health and Human Services (DHHS). (2019, March 6). Michigan opioid laws. Retrieved from https://www.michigan.gov/documents/lara/LARA\_DHHS\_Opioid\_Laws\_FAQ\_05-02-2018\_622175\_7.pdf
- (1) National Institute on Drug Abuse. (2019, January 29). Overdose death rates. Retrieved from https://www.drugabuse.gov/related-topics/trends-statistics/overdose-death-rates